Will Enasidenib be included in Medicare in 2025?

As of2025, ensidipine (Enasidenib) has not been officially launched in my country, and therefore has not been included in the national medical insurance directory. This means that if domestic patients need to use the drug, they can only rely on overseas channels to purchase it themselves, and the related expenses cannot be reimbursed through medical insurance. As a drug targeting IDH2 mutations, ensidipine is mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML). Its clinical effect has been confirmed abroad, but it is still in the blank stage before introduction in my country.

Since it has not yet been approved for marketing in China, the acquisition of Encidipine generic drugs mainly relies on overseas markets. Common specifications of original drugs currently sold overseas include 50mg30 tablets and 100mg30 tablets. The price is relatively expensive, and may be as high as about 300,000 yuan per box (the price may change due to exchange rate fluctuations). Such high expenses pose a huge financial burden to patients who need to take them for a long time, especially when there is no medical insurance support.

In order to reduce the cost of treatment, some patients will choose overseas generic drugs as an alternative. For example, Lucius Pharmaceutical Factory in Laos has launched a generic version of ensidipine with a specification of 50mg*30 tablets. The price per box is about more than 1,000 yuan, which is more cost-effective. Although it is a generic drug, its active ingredients are basically the same as those of the original drug, and it can still play a good therapeutic role for most patients. However, when choosing generic drugs, it is still recommended that patients proceed under the guidance of a professional doctor to ensure the standardization and safety of treatment.

To sum up, ensidipine has not yet entered my country's medical insurance catalog in2025, mainly because it has not yet completed the domestic registration and approval process. Currently, patients can purchase original drugs or generic drugs from overseas through formal channels, but they need to bear all costs. In the future, if the drug is successfully launched in China and entered into medical insurance, patients' medication burden is expected to be significantly reduced and the accessibility of treatment will be further improved.

Reference materials:https://www.idhifa.com/